Vital Therapies Inc Stock Nasdaq
Equities
US92847R1041
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 109M |
---|---|---|---|---|---|
Net income 2024 * | -93M | Net income 2025 * | -104M | EV / Sales 2024 * | - |
Net cash position 2024 * | 33.12M | Net Debt 2025 * | 55.55M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.22
x | P/E ratio 2025 * |
-1.22
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.28% |
Latest transcript on Vital Therapies Inc
Managers | Title | Age | Since |
---|---|---|---|
Daniel Vitt
CEO | Chief Executive Officer | 55 | 16-12-31 |
Glenn Whaley
DFI | Director of Finance/CFO | 56 | 19-11-30 |
Hella Kohlhof
CTO | Chief Tech/Sci/R&D Officer | 51 | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Barclay Phillips
BRD | Director/Board Member | 61 | 19-11-18 |
Tamar Howson
BRD | Director/Board Member | 75 | 19-10-10 |
Jörg Neermann
BRD | Director/Board Member | 57 | 19-03-31 |
1st Jan change | Capi. | |
---|---|---|
-3.39% | 102B | |
+2.61% | 96.84B | |
-0.82% | 21.48B | |
-18.14% | 20.82B | |
-7.26% | 18.6B | |
-40.70% | 16.81B | |
-26.89% | 13.78B | |
+1.12% | 13.4B | |
+22.25% | 11.06B |